Online inquiry

IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3344MR)

This product GTTS-WQ3344MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets VEGFA gene. The antibody can be applied in Cancers research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7422
UniProt ID P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VEGFA, AT-001(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ3344MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ13340MR IVTScrip™ mRNA-Anti-PDCD1, PF-06801591(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06801591
GTTS-WQ11086MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ2489MR IVTScrip™ mRNA-Anti-CD3E&FOLH1, AMG 212(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AMG 212
GTTS-WQ12464MR IVTScrip™ mRNA-Anti-IL2RB, NKTR-214(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA NKTR-214
GTTS-WQ12568MR IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA NV-02
GTTS-WQ13664MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ6911MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ1231MR IVTScrip™ mRNA-Anti-TPBG, ABR-217620(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ABR-217620
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW